Tacrolimus plus low-dose mycophenolate mofetil in renal transplant recipients: Better 2-year graft and patient survival than with a higher mycophenolate mofetil dose

KOCAK, HÜSEYİN; YAKUPOGLU, U; KARATAS, GU; YAVUZ, A; GÜRKAN, AYSEL; Erdogan, OKAN; ERSOY, FETTAH; YAKUPOGLU, G; DEMIRBAS, A; TUNCER, M

doi:10.1016/j.transproceed.2005.07.033

Tacrolimus plus low-dose mycophenolate mofetil in renal transplant recipients: Better 2-year graft and patient survival than with a higher mycophenolate mofetil dose

Atıf İçin Kopyala

KOCAK H., YAKUPOGLU U., KARATAS G., YAVUZ A., GÜRKAN A., Erdogan O., ...Daha Fazla

TRANSPLANTATION PROCEEDINGS, cilt.37, sa.7, ss.3009-3011, 2005 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 37 Sayı: 7
Basım Tarihi: 2005
Doi Numarası: 10.1016/j.transproceed.2005.07.033
Dergi Adı: TRANSPLANTATION PROCEEDINGS
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.3009-3011
Akdeniz Üniversitesi Adresli: Evet

Özet

Objectives. Mycophenolate mofetil (MMF) has become more widely prescribed in recent years, but its adverse effects on the gastrointestinal system and bone marrow restrict its use in certain settings. The aim of this study was to compare the demographic features and clinical data for 173 renal transplant recipients who received tacrolimus (TAC) plus 1 g/d MMF (group I, n = 112) versus TAC plus 2 g/d MMF (group II, n = 61 patients) over a 2-year period. Each patient received similar TAC doses.